Some markers, like PD-L1 expression and tumor mutation burden (TMB), have been applied in clinical lung cancer cases for predicting patients’ immunotherapy responses [7], whereas tumor heterogeneity is still a great challenge in clinical practice of cancers. Here, CD274 is linked to neoplasm.